reports
Psychemedics Corporation Reports 2023 Financial Results
Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reducti...
Psychemedics Recognized as a Top 10 Employee Health Testing Services P...
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing. ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee heal...
Psychemedics Corporation Announces Relocation of Headquarters to Dalla...
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its diverse cliente...
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance
Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in st...
Psychemedics Corporation Reports Third Quarter 2023 Financial Results
Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.0...
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced...
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen Psychemedics’ FDA-cleared alternative 5-panel drug screen replaces marijuana with fentanyl. ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat o...
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue O...
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. ...
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listin...
Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards were grant...
Psychemedics Corporation Reports Second Quarter 2023 Financial Results
Psychemedics Corporation Reports Second Quarter 2023 Financial Results ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per di...
Psychemedics Corporation Announces CEO Succession Plan
Psychemedics Corporation Announces CEO Succession Plan Brian Hullinger Will Succeed Ray Kubacki as CEO Effective August 17, 2023 Mr. Hullinger Brings 30 Years of Leadership Experience and a Proven Track Record of Driving Growth ACTON, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today that its board of directors has approved a transition plan for the Company’s President and CEO position. Effective August 17th, current Chairman of the Board, President, and CEO, Ray Kubacki, ...
Psychemedics Corporation Reports First Quarter 2023 Financial Results ...
Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company’s revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, ...
Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Fin...
Psychemedics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2022. The Company also announced a quarterly cash dividend of $0.07 per share payable to shareholders of record as of March 31,2023, to be paid on April 10,2023. The Company's revenue for the year ended December 31, 2022,...
Psychemedics Corporation Reports Third Quarter 2022 Financial Results ...
Psychemedics Corporation Reports Third Quarter 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2022. The Company also announced a cash quarterly dividend of $0.07 per share payable to the shareholders of record as of December 2, 2022, to be paid on December 16, 2022. The Company’s revenue for the quarter ended September 30, 2022, was $6.5 million vers...
Psychemedics Corporation Reports Second Quarter 2022 Financial Results...
Psychemedics Corporation Reports Second Quarter 2022 Financial Results and Declares Quarterly Cash Dividend ACTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022. The Company also announced a quarterly dividend of $0.07 per share payable to the shareholders of record as of August 24, 2022, to be paid on September 9, 2022. The Company’s revenue for the quarter ended June 30, 2022, was $6.5 million versus $6.1 mill...
Psychemedics Announces Two New Director Nominees for its 2022 Annual M...
Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.’s Retirement after More than 20 Years of Dedicated Service ACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced today that it will be nominating Peter H. Kamin and Darius G. Nevin to serve as new members of its Board of Directors at its upcoming Annual Meeting of Stockholders to be held on August 12, 2022, and that Walter S. Tomenson, Jr. will be retiring from the Board as of the completion of his current term ending ...
Psychemedics Corporation Reports First Quarter 2022 Financial Results ...
Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend ACTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per share to be paid on June 24, 2022, to shareholders of record as of May 27, 2022. The Company’s revenue for the quarter ended March 31, 2022, was $6.5 million versus $5.7 million for the quarter ended March...
- Jonathan Moreland
SXT SENSIENT TECHNOLOGIES CORPORATION
HMTV HEMISPHERE MEDIA GROUP
ECL ECOLAB INC.
DIOD DIODES INCORPORATED
PMD PSYCHEMEDICS CORP.
OCX ONCOCYTE
NNBR NN
LQDA INC.
BATRA LIQUIDIA CORPORATION
ZM LIBERTY BRAVES SERIES A
PNTG ZOOM VIDEO COMMUNICATIONS
ALTG INC.
BDTX PENNANT GROUP
GRPN ALTA EQUIPMENT GROUP INC.
INZY BLACK DIAMOND THERAPEUTICS
YAYO INC.
AFRM GROUPON INC.
PHX INOZYME PHARMA
CRCT RIDESHARE RENTAL INC
DUOL AFFIRM HOLDINGS
ATAI PANHANDLE OIL AND GAS INC
NYC CRICUT
MYPS INC.
DUOLINGO
INC.
ATAI LIFE SCIENCES BV
NEW YORK CITY REIT INC
PLAYSTUDIOS INC
- Jonathan Moreland
- Jonathan Moreland
SXT SENSIENT TECHNOLOGIES CORPORATION
PRTY PARTY CITY HOLDCO INC.
HMTV HEMISPHERE MEDIA GROUP
QRHC QUEST RESOURCE HOLDING
MLI MUELLER INDUSTRIES INC.
PMD PSYCHEMEDICS CORP.
OCX ONCOCYTE
CDZI CADIZ INC.
MRSN MERSANA THERAPEUTICS
CNNE CANNAE HOLDINGS
QNTO QUAINT OAK BANCORP INC.
MMD MAINSTAY DEFINEDTERM MUNICIPAL HIGH INCOME FUND
STIM STIMSONITE CORP
TRVI TREVI THERAPEUTICS
PNTG PENNANT GROUP
PINE ALPINE INCOME PROPERTY TRUST
BDTX BLACK DIAMOND THERAPEUTICS
LYRA INC.
TARA LYRA THERAPEUTICS
IHRT INC.
CCCC PROTEON THERAPEUTICS INC
GRPN IHEARTMEDIA INC. CLASS A
BDSX C4 THERAPEUTICS
JAKK GROUPON INC.
INDT BIODESIX
CRCT JAKKS PACIFIC INC.
AEI INDUS REALTY TRUST INC
GRPH CRICUT
ATAI INC.
FORA ALSET EHOME INTERNATIONAL INC
NYC GRAPHITE BIO
YOU INC.
MYPS ATAI LIFE SCIENCES BV
ABIO FORIAN INC
NEW YORK CITY REIT INC
CLEAR SECURE INC
PLAYSTUDIOS INC
ARCA BIOPHARMA INC
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.